Shillong Herald

Developmental and Epileptic Encephalopathy Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight

 Breaking News
  • No posts were found

Developmental and Epileptic Encephalopathy Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight

January 23
18:28 2023
Developmental and Epileptic Encephalopathy Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight
Developmental and Epileptic Encephalopathy Pipeline Insights
United States, Nevada, Las Vegas, DelveInsight’s ‘Developmental and Epileptic Encephalopathy Pipeline Insight 2022’ report provides comprehensive global coverage of available, marketed, and pipeline Developmental and Epileptic Encephalopathy therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Developmental and Epileptic Encephalopathy pipeline domain.

United States, Nevada, Las Vegas, DelveInsight’s Developmental and Epileptic Encephalopathy Pipeline Insight 2023 report provides comprehensive global coverage of available, marketed, and pipeline Developmental and Epileptic Encephalopathy therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Developmental and Epileptic Encephalopathy pipeline domain.

Key Takeaways from the Developmental and Epileptic Encephalopathy Pipeline Report

  • Over 10+ Developmental and Epileptic Encephalopathy pipeline therapies are in various stages of development, and their anticipated acceptance in the Developmental and Epileptic Encephalopathy market would significantly increase market revenue. 
  • Leading Developmental and Epileptic Encephalopathy companies developing novel drug candidates to improve the Developmental and Epileptic Encephalopathy treatment landscape include Jazz Pharmaceuticals, Biocodex, Zogenix (Acquired by UCB), Lundbeck, and others.
  • Promising Developmental and Epileptic Encephalopathy pipeline therapies in various stages of development include Epidiolex (Cannabidol), Diacomit (Stiripentol), Fintepla (Fenfluramine), Sabril (Vigabatrin), and others.

Developmental and Epileptic Encephalopathy Overview

Developmental and Epileptic Encephalopathy (DEE) refers to a group of severe epilepsies that are characterized both by seizures, which are often drug-resistant, as well as encephalopathy, which is a term used to describe significant developmental delay or even loss of developmental skills. The syndromes of epileptic encephalopathies with onset in the neonatal period, infancy, and early childhood include early myoclonic encephalopathy, Ohtahara syndrome, West syndrome, Dravet syndrome (severe myoclonic epilepsy in infancy), Lennox–Gastaut syndrome (LGS), Landau–Kleffner syndrome (LKS), Epilepsy with continuous spike-and-waves during slow-wave sleep, Doose Syndrome (myoclonic atonic epilepsy), CDKL5 deficiency disorder (CDD), Tuberous sclerosis complex (TSC), SCN8A-DEE, and KCNQ2-DEE.

Developmental and Epileptic Encephalopathy Pipeline Analysis: Drug Profile

Epidiolex (Cannabidol): Jazz Pharmaceuticals

Epidiolex (formerly GWP42003-P), also known as Epidyolex in Europe, is the first prescription, plant-derived cannabis oral formulation developed by GW pharmaceuticals. It is a novel class of antiepileptic medications with a different mechanism of action. It has been approved in the US and Europe for the treatment of seizures associated with LGS or Dravet syndrome in patients 2 years of age and older. The drug is the first FDA-approved drug that contains a purified drug substance derived from marijuana, and the active ingredient is cannabidiol (CBD).

Discover more about the emerging Developmental and Epileptic Encephalopathy drugs @ Developmental and Epileptic Encephalopathy Treatment Drugs

Developmental and Epileptic Encephalopathy Key Companies

  • Jazz Pharmaceuticals
  • Biocodex
  • Zogenix (Acquired by UCB)
  • Lundbeck

Developmental and Epileptic Encephalopathy Pipeline Therapies

  • Epidiolex (Cannabidol)
  • Diacomit (Stiripentol)
  • Fintepla (Fenfluramine)
  • Sabril (Vigabatrin)

Developmental and Epileptic Encephalopathy Pipeline Therapeutics Assessment

  • By development stage
  • By product type
  • By route of administration
  • By molecule type
  • By MOA type 

Scope of the Developmental and Epileptic Encephalopathy Pipeline Report 

  • Coverage: Global 
  • Key Developmental and Epileptic Encephalopathy Companies: Jazz Pharmaceuticals, Biocodex, Zogenix (Acquired by UCB), Lundbeck, and others
  • Key Developmental and Epileptic Encephalopathy Pipeline Therapies: Epidiolex (Cannabidol), Diacomit (Stiripentol), Fintepla (Fenfluramine), Sabril (Vigabatrin), and others

Find out more about the Developmental and Epileptic Encephalopathy treatment options in development @ Developmental and Epileptic Encephalopathy Clinical Trials

Table of Contents

1. Introduction

2. Executive Summary

3. Overview

4. Pipeline Therapeutics

5. Late-Stage Products (Phase III)

6. Mid-Stage Products (Phase  II)

7. Early Stage Products (Phase  I/II)

8. Preclinical Stage Products

9. Discovery Stage Products

10. Therapeutic Assessment

11. Inactive Products

12. Collaborations Assessment- Licensing / Partnering / Funding

13. Unmet Needs

14. Market Drivers and Barriers

15. Appendix

16. About DelveInsight

Request for a sample report to know more about the leading companies in the diabetic epileptic encephalopathy pipeline domain.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Related Articles